Brain Cancer

P2, N=75, Recruiting, Institut de cancérologie Strasbourg Europe | Not yet recruiting --> Recruiting | Trial completion date: Mar 2027 --> Jul 2029 | Trial primary completion date: Mar 2027 --> Jul 2028

P=N/A, N=30, Active, not recruiting, Centre Hospitalier Universitaire de Nice | Completed --> Active, not recruiting | Trial completion date: Mar 2025 --> Mar 2026

P1, N=12, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting

This trial has been approved by the Institutional Review Board (IRB) and began patient enrollment in January 2024. The trial will provide insights into the safety and effectiveness of a novel combinatorial therapy for BCBM.

Indeed, orthotopic implantation of MET-expressing GBM cells corroborates their superior tumor-initiating and invasive capabilities. Thus, pericytes represent critical modulators of GBM development by orchestrating a tumor-suppressive microenvironment, highlighting the importance of their preservation in therapy.

Glioblastoma mounts a spatial self-protective defense through IL-8-driven TSR formation that restricts oncolytic virus spread. IL-8 functions as both a pharmacodynamic biomarker and a therapeutic target, and its inhibition provides a rational strategy to overcome resistance and optimize GBM virotherapy.

Moreover, GBM tissue samples showed LARG S1288 phosphorylation and RhoA-GTP-bound RhoA. Elucidating the regulatory mechanisms governing this process is crucial for the development of LARG-targeted therapeutic interventions.

FACS analysis showed loss of co-stimulatory CD80, an immune synapse component, following B3gat1 knockdown. These results suggest that loss of HNK-1 expression contributes to tumor immune escape through loss of immune recognition and attack via downregulation of tumor cell surface co-stimulatory molecules, leading to reduced CD8+ T-cell activation and immune synapse formation, and increased T-cell apoptosis.

P=N/A, N=228, Not yet recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Trial completion date: Apr 2028 --> Oct 2028 | Trial primary completion date: Oct 2026 --> Apr 2027

P1, N=12, Not yet recruiting, Neonc Technologies, Inc. | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

P1, N=11, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 11

Although intergroup differences were limited, our intragroup analyses revealed reduced satiety persistence and earlier appetite rebound, particularly in patients with HyOb and severe HI, providing new insights into the complex, multifactorial pathophysiology of HyOb associated with aCP.